Atlas Capital Advisors LLC Uni Qure N.V. Transaction History

Atlas Capital Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	BUY	$16.98 - $25.54 $13,770 - $20,712	811 New	811 $15.2 Million
Q2 2022 Aug 16, 2022	SELL	$13.15 - $20.45 $10,664 - $16,584	-811 Closed	0 $0
Q2 2021 Jul 30, 2021	BUY	$29.97 - $37.17 $4,945 - $6,133	165 Added 25.54%	811 $24,000
Q1 2021 May 10, 2021	BUY	$29.24 - $42.03 $16,959 - $24,377	580 Added 878.79%	646 $21,000
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $2,333 - $3,344	66 New	66 $2,000

154

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $280M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Atlas Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Atlas Capital Advisors LLC with notifications on news.